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DOI 10.1186/s12883-017-0904-4RESEARCH ARTICLE Open AccessCo-morbidity and polypharmacy in
Parkinson’s disease: insights from a large
Scottish primary care database
Gary McLean1, John V. Hindle2, Bruce Guthrie3 and Stewart W. Mercer1*Abstract
Background: Parkinson’s disease is complicated by comorbidity and polypharmacy, but the extent and patterns of
these are unclear. We describe comorbidity and polypharmacy in patients with and without Parkinson’s disease
across 31 other physical, and seven mental health conditions.
Methods: We analysed primary health-care data on 510,502 adults aged 55 and over. We generated standardised
prevalence rates by age-groups, gender, and neighbourhood deprivation, then calculated age, sex and deprivation
adjusted odds ratios (OR) and 95% confidence intervals (95% CI) for those with PD compared to those without, for
the prevalence, and number of conditions.
Results: Two thousand six hundred forty (0.5%) had Parkinson’s disease, of whom only 7.4% had no other conditions
compared with 22.9% of controls (adjusted OR [aOR] 0.43, 95% 0.38–0.49). The Parkinson’s group had more conditions,
with the biggest difference found for seven or more conditions (PD 12.1% vs. controls 3.9%; aOR 2.08 95% CI 1.84–2.35).
12 of the 31 physical conditions and five of the seven mental health conditions were significantly more prevalent in the
PD group. 44.5% with Parkinson’s disease were on five to nine repeat prescriptions compared to 24.5% of controls (aOR
1.40; 95% CI 1.28 to 1.53) and 19.2% on ten or more compared to 6.2% of controls (aOR 1.90; 95% CI 1.68 to 2.15).
Conclusions: Parkinson’s disease is associated with substantial physical and mental co-morbidity. Polypharmacy is also a
significant issue due to the complex nature of the disease and associated treatments.Background
Parkinson disease (PD) is a chronic, progressive neuro-
degenerative disease characterized by slowness of move-
ment (bradykinesia) together with at least one of rest
tremor, rigidity, and postural instability [1]. The onset of
PD is rare before age 50 years and there is a sharp
increase in incidence after age 60 years, such that PD
has been reported as the second most common chronic
neurodegenerative condition in older people in Europe
after Alzheimer’s Disease [1, 2] . Although estimates of
its true prevalence vary [2, 3], it is thought that it is
present in about 0.3% of the general population and 1%
of those over 60 years with an incidence of 8–18 per
100,000 person years [4]. Ageing populations are likely
to lead to large increases in the prevalence of PD with* Correspondence: Stewart.mercer@glasgow.ac.uk
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(http://creativecommons.org/publicdomain/zeestimates in UK suggesting that it may rise by as much
as 26% by 2020 and double worldwide by 2030 [5, 6].
While PD is primarily characterised by motor symp-
toms, it is also associated with the development of a
spectrum of non-motor symptoms as well as a number
of related comorbid conditions. The non-motor symp-
toms include autonomic dysfunction affecting the car-
diovascular, genitourinary and gastrointestinal systems
as well as dysfunction of the respiratory system, skin,
eyes and ears [7]. There may also be significant mental
health disturbance with the development of depression
and anxiety, psychosis, apathy, and fatigue as well as
dementia as the disease advances [8, 9]. PD may also be
associated with an increased risk of falls and osteopor-
osis [10]. The non-motor symptoms significantly ad-
versely impact quality of life. The complex nature of PD
and its co-morbidities may be particularly challenging
for both the patient and health service provider to deal
with due to health services being typically organisedle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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multiple conditions receiving uncoordinated or fragmen-
ted care [11, 12]. In addition people with multiple
conditions commonly face problems with regard to poly-
pharmacy and consequent risk of adverse drug events
and issues with drug adherence [13].
A number of studies have reported the prevalence of
co-morbidity in old people with PD but most have fo-
cused on single conditions and particularly mental
health problems, finding high levels of depression and
psychosis [14, 15]. Studies which have included multiple
conditions have tended to be small in size and focused
on the effect on issues such as mobility [16]. One study
specifically looked at the spectrum of co-morbidity in an
incident PD cohort of 197 people in the 5 years before
disease onset and the subsequent 15 years compared
with a matched control group using a summary co-
morbidity score (Charlson Index) and the likelihood of
having one or more diagnoses within each International
Classification of Diseases chapter/subchapter [17]. Be-
fore the onset of PD there was no difference in the
spectrum of co-morbid disorders, but after diagnosis
there was greater morbidity compared with controls
with the excess morbidity reflecting either the cardinal
features of PD, recognized sequelae of PD, or PD
complications [17]. A Dutch study in general practice
assessed the levels of co-morbidity in seven neurological
disorders including PD and depression. Stroke, dementia
and depression were identified as the commonest co-
morbidities in PD [18].
The nature of the treatment for the motor and non-
motor symptoms of PD means that patients almost
inevitably end up on complex medication regimes. One
case control study in Taiwan analysed the drug history
in a two-year period prior to PD onset [19]. The results
suggested that polypharmacy was greater in people who
developed PD but the detailed nature of this relationship
was unclear. Co-morbid conditions which were more
common in PD included dementia, stroke, depression,
and alcoholism. Hyperlipidaemia was inversely associ-
ated with PD.
There is still a need to examine the detailed relation-
ship between PD, other conditions and associated
prescribing in larger populations, in order to better
understand the burden of comorbidity and polyphar-
macy. Therefore, this paper examines the prevalence of
physical and mental health co-morbidity and polyphar-
macy in people with and without PD in a large popula-
tion cohort of people aged 55 years and over.
Methods
We obtained data from the Primary Care Clinical
Informatics Unit at the University of Aberdeen for all
510,542 patients aged 55 and over who were alive andpermanently registered with one of 314 Scottish general
practices on March 31, 2007 [20]. Data on the presence
of PD, 31 other common chronic physical health condi-
tions and 7 mental health conditions were extracted
(listed in Appendix 1). The dataset is representative of
the whole Scottish population in terms of age, sex and
socioeconomic deprivation, with a more detailed explan-
ation available elsewhere [21]. We defined PD using a
set of Read Codes used by NHS Scotland Information
Services Division for this purpose. Read Codes are a
coded thesaurus of clinical terms used in the NHS since
1985. They provide a standard vocabulary for clinicians
to record patients findings and procedures across both
primary and secondary care. For the purpose of this
study we defined someone as having PD if they had a
Read Code recorded of F11x9 (Cerebral degeneration in
Parkinson’s disease), F12..(Parkinson’s disease), F120.Par-
alysis agitans.,F12z. (Parkinson’s disease NOS), F1303
(Parkinsonism with orthostatic hypotension).
To control for differences between the two popula-
tions in age, gender and socioeconomic deprivation we
adopted a similar approach to that undertaken in previ-
ous papers [22–24]. We generated standardised preva-
lence rates by age groups (55 to 64; 65 to 74; 75 to 84
and 85 and over), gender and deprivation decile using
the direct method, using a bonferroni correction for
multiple comparisons. In direct standardization, esti-
mated rates are adjusted according to the frequency
distribution of a standard population (in this case the
control group). The standard population is partitioned
into categories, called standard strata based on the age
group-gender and deprivation quintile of the individual.
A weighted sum of the point estimates from the stand-
ard strata is used to produce an overall point estimate
for the population. From this standardised prevalence,
rates are calculated for the PD and control groups.
These age-gender-deprivation standardised rates were
then used to calculate age, sex, and deprivation adjusted
odds ratio (ORs), and 95% confidence intervals (95% CI)
for the adults with PD compared to those without (con-
trols), for the prevalence of 31 other physical conditions
and seven mental health conditions as well as by the
number of overall morbidities (total physical + mental
conditions) and the number of physical and mental
health conditions.
Data on the number of drugs authorised for repeat pre-
scription and issued in the previous 84 days were
extracted. We chose 84 days (12 weeks) to ensure that
short-term prescribing for acute conditions was not in-
cluded. The count of number of repeat prescription drugs
includes all pharmacologically active drugs, but excludes
devices, dressings and topical preparations without signifi-
cant systemic effects. Socioeconomic deprivation was
measured using the Carstairs deprivation score divided
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on postcode of residence and is widely used in healthcare
research as a measure of socioeconomic status. We used t
tests to analyse differences between groups and one-way
analysis of variance for differences across age groups and
deprivation deciles. For all statistical analyses, a p < 0·05
was considered statistically significant. All analyses were
performed in Stata version 13. The NHS Grampian
Research Ethics Service approved the anonymous use of
these data for research purposes, thefore this study did
not require individual ethics approval.Results
Demographics
There were 2640 (0.5% of the total population patients
with a Read Code for PD recorded (Table 1). Men were
over-represented in the PD group compared with con-
trols (55.3% vs. 45.8% for controls; p < 0.001). Individ-
uals with PD were on average much older (mean age
76.4 years vs. 68.2 years for controls; p < 0.001), with
61% aged 75 or over compared with 26.4% of controls
(p < 0.001). There was little difference found by distribu-
tions in deprivation quintiles.Comorbidities
Overall, 7.4% of individuals with PD had no other condi-
tions compared with 22.9% of controls (OR 0.43 95% CI
0.38–0.49 (Table 2). There were significant differences
between the PD and control groups, after standardising
for age, sex, and deprivation for five, six and seven or
more comorbidities. For example, 30.9% had five or
more conditions compared with 13.2% of controls
(p < 0.001) with the biggest difference found for sevenTable 1 Age, gender and deprivation status, PD versus controls
Variable PD Number (%) No PD Number (%)
Total (%) 2640 (0.5) 507,862 (99.5)
Gender (% male) 1459 (55.3) 232,602 (45.8)
Mean Age (sd) 76.4 (9.1) 68.2 (9.7)
Age group
55–64 308 (11.7) 219,025 (43.1)
65–74 722 (27.3) 154,558 (30.4)
75–84 1084 (41.1) 98,236 (19.3)
85 and above 526 (19.9) 36,043 (7.1)
Deprivation Quintile
Least Deprived 562 (21.3) 99,489 (19.6)
2 635 (24.0) 117,794 (23.2)
3 612 (23.2) 117,011 (23.0)
4 464 (17.6) 93,013 (18.3)
Most Deprived 367 (13.9) 80,555 (15.9)or more conditions (PD 12.1% vs. controls 3.9%; OR
2.08 95% CI 1.84–2.35) (table 2).
Restricting analysis only to physical health comorbidi-
ties showed a similar trend to total number of morbid-
ities although differences were slightly smaller. Those
with PD were less likely to have no physical conditions
(PD 11.8% vs. controls 25.6%; OR 0.65 95% CI 0.58–
0.74) with biggest difference again found for seven or
more physical conditions (PD 5.2% vs. controls 2.0%; OR
1.52 95% CI 1.27–1.86). Table 2 also shows high levels of
mental health in the PD group with 44% having at least
one mental health condition. People with PD were less
likely to have no recorded mental health condition com-
pared with controls (PD 56.0% vs. controls 80.0%; OR
0.33, 95% CI 0.30–0.36), and more than twice as likely
to have one mental health condition (PD 27.2% vs. con-
trols 14.6%; OR 2.09, 95% CI 1.92–2.87) than people
without PD.
Physical health individual conditions
Very high raw prevalence rates were found for people with
PD for hypertension (41.1%), constipation (27.5%), coron-
ary heart disease (25.1%) and painful conditions (21.7%).
After standardisation for age, sex and deprivation, 12 out
of 30 physical conditions were significantly more prevalent
in the PD group relative to controls with 17 conditions
showing no significant difference and two conditions
(hypertension and chronic kidney disease [CKD]) signifi-
cantly less prevalent (Table 3). The biggest differences
after standardisation for age, sex and deprivation were for
constipation (OR 3.92, 95% CI 3.57–4.31) and epilepsy
(OR 1.79 95% CI 1.34–2.40).
Mental health conditions
Table 4 shows that those with PD had significantly
higher prevalence for four of the six mental health con-
ditions with no significant difference found for alcohol
misuse and anorexia or bulimia. The highest prevalence
for a mental health condition was found for depression
with prevalence 28.0% for those with PD compared with
12.4% of controls (OR 3.02 95%CI 2.76–3.29). The big-
gest difference after standardisation for age, sex and
deprivation was for schizophrenia or bipolar disease (PD
3.5% vs. controls 1.0%; OR 3.77, 95% CI 3.05–4.66),
followed by dementia (PD 12.2% vs. controls 2.1%; OR
3.31, 95% CI 2.91–3.77).
Polypharmacy in people with PD versus controls
People with PD were on average on more active repeat
prescriptions (mean number of repeats 6.2 vs. 3.3;
p < 0.001). Table 5 shows that only 7.2% of those with PD
were not on a repeat prescription compared with 29.3% of
controls (OR 0.38; 95% CI 0.32 to 0.45; p < 0.001). In total
73.3% with PD were on five or more repeat prescriptions
Table 2 Prevalence and odds ratio for number and type of comorbidities (standardised by age, gender and deprivation score)
Parkinson’s
N (prevalence %)
N = 2640 (0.5%)
No Parkinson’s
N (prevalence %)
N = 507,862 (99.5%)
Odds ratio (95% CI) (standardised
by age, gender and deprivation)b
Total number of morbiditiesa
None 195 (7.4) 116,358 (22.9) 0.43 (0.38–0.49)
One 376 (14.3) 113,634 (22.4) 0.81 (0.73–0.89)
Two 487 (18.5) 94,062 (18.5) 0.99 (0.90–1.09)
Three 430 (16.3) 69,525 (13.7) 1.01 (0.91–1.12)
Four 355 (12.7) 47,109 (9.3) 1.05 (0.94–1.19)
Five 291 (11.0) 29,601 (5.8) 1.38 (1.22–1.56)
Six 208 (7.8) 17,800 (3.5) 1.56 (1.35–1.81)
Seven or more 318 (12.0) 19,773 (3.9) 2.08 (1.84–2.35)
Total number of physical conditionsa
None 311 (11.8) 129,846 (25.6) 0.65 (0.58–0.74)
One 509 (19.3) 123,984 (24.4) 0.90 (0.82–1.00)
Two 558 (21.1) 99,187 (19.5) 1.03 (0.94–1.13)
Three 444 (16.8) 67,710 (13.3) 1.02 (0.92–1.14)
Four 327 (12.4) 41,539 (8.1) 1.10 (0.98–1.23)
Five 233 (8.8) 23,414 (4.6) 1.30 (1.13–1.47)
Six 121 (4.5) 12,078 (2.4) 1.19 (1.01–1.37)
Seven or more 137 (5.2) 10,104 (2.0) 1.52 (1.27–1.86)
Total number of mental health conditions
None 1477 (56.0) 406,379 (80.0) 0.33 (0.30–0.36)
One 718 (27.2) 74,234 (14.6) 2.09 (1.92–2.27)
Two 376 (14.2) 23,583 (4.6) 3.08 (2.75–3.45)
Three or more 69 (2.6) 3666 (0.7) 3.14 (2.46–4.00)
aExcluding PD. Includes all other physical + mental conditions
bAll differences significant at p < 0.001
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with 24.5% of controls (OR 1.40; 95% CI 1.28 to 1.53;
p < 0.001) and 19.2% on ten or more compared with 6.2%
of controls (OR 1.90; 95% CI 1.68 to 2.15; p < 0.001).
Discussion
This large study of a representative UK population dem-
onstrates that people with PD are more likely to have
very high levels of co-morbidity and less likely to have
no co-morbid conditions than controls. The results show
a higher level of both physical and mental co-morbidity
compared with controls with 12 physical and 5 mental
conditions being more common in PD. The results are
consistent with previous studies showing that co-
morbidities in PD are often related to the wide effects of
the disease itself [19–24].
Comparison with other studies
Physical co-morbidity
The physical conditions which showed the biggest
differences in prevalence compared with controls afterstandardisation were constipation and epilepsy. Consti-
pation is a feature of PD itself, may occur many years
before the onset of the motor disorder [25] and may be
due to the early presence of PD pathology in the neur-
onal plexus in the bowel [26]. There is no known causal
link between epilepsy and PD and epilepsy has not pre-
viously been recorded as a common co-morbid condi-
tion in PD. It could be that some patients documented
with PD have drug-induced Parkinsonism (for example
due to sodium valproate) or co-morbid stroke, which
was also more prevalent in PD. The increased prevalence
of visual dysfunction in the PD group may reflect the
complex visual dysfunctions which are now known to be
common in PD [27].The increased prevalence of painful
disorders, irritable bowel, prostate disorder (which could
mimicked by bladder sphincter problems in PD) and
dyspepsia could all feasibly be explained by the known
non-motor complications of PD [8]. The increased
prevalence of coronary heart disease in PD is an import-
ant finding since comorbid vascular disease, including
coronary disease is known to have an adverse effect on
Table 3 Prevalence and odds ratios for individual physical conditions (standardised by age, gender and deprivation score).
Conditions are ordered by size of odds ratio (largest to smallest)
Condition Parkinson’s
N (prevalence %)
N = 2640
No Parkinson’s
N (prevalence %)
N = 507,862
Odds ratio (95% CI) (standardised
by age, gender and deprivation)a
Constipation 725 (27.5) 29,629 (5.8) 3.92 (3.57–4.31)
Viral hepatitis 1 (0.0) 1684 (0.0) 2.03 (0.27–14.99) p = 0.48
Epilepsy 47 (1.8) 5109 (1.0) 1.79 (1.34–2.40)
Multiple sclerosis 9 (0.3) 1683 (0.3) 1.53 (0.79–2.97) p = 0.20
Visual impairment 77 (2.9) 6297 (1.2) 1.37 (1.09–1.73)
Stroke or transient ischaemic attack 363 (13.8) 33,146 (6.5) 1.37 (1.22–1.53)
Painful condition 573 (21.7) 85,233 (16.8) 1.34 (1.22–1.47)
Irritable bowel syndrome 123 (4.6) 21,903 (4.3) 1.33 (1.11–1.60)
Cirrhosis/chronic liver disease/alcoholic liver disease 9 (0.3) 1684 (0.3) 1.27 (0.66–2.46) p = 0.46
Coronary heart disease 664 (25.2) 74,789 (14.7) 1.22 (1.11–1.33)
Prostate disease 155 (5.9) 13,252 (2.6) 1.25 (1.05–1.48)
Heart failure 178 (6.7) 17,193 (3.4) 1.17 (1.00–1.37) p = 0.04
Any new cancer in the last 5 years 267 (10.1) 32,629 (6.4) 1.16 (1.02–1.32) p = 0.02
Thyrotoxicosis/thyroid disorders incl. Hypothyroidism 291 (11.0) 47,874 (9.4) 1.15 (1.01–1.31)
Glaucoma 135 (5.1) 14,166 (2.8) 1.15 (0.96–1.37) p = 0.10
Dyspepsia 326 (12.4) 51,172 (10.1) 1.13 (1.01–1.22)
Peripheral vascular disease (PVD) 150 (5.7) 18,800 (3.7) 1.08 (0.91–1.28) p = 0.34
Diverticular disease 239 (9.1) 30,692 (6.0) 1.06 (0.92–1.21) p = 0.38
Atrial fibrillation 212 (8.0) 22,378 (4.4) 1.03 (0.89–1.18) p = 0.67
Diabetes 348 (13.2) 55,548 (10.9) 1.02 (0.91–1.14) p = 0.72
Inflammatory arthritis and related conditions incl. Gout 269 (10.2) 41,973 (8.3) 1.02 (0.90–1.16) p = 0.71
Inflammatory bowel disease 25 (0.9) 4787 (0.9) 1.02 (0.69–1.52) p = 0.89
Hearing loss 284 (10.8) 36,486 (7.2) 1.01 (0.89–1.14) p = 0.89
Psoriasis or eczema 26 (0.9) 4775 (0.9) 0.93 (0.63–1.08) p = 0.74
Chronic sinusitis 17 (0.6) 4334 (0.9) 0.91 (0.56–1.47) p = 0.70
Active asthma 141 (5.3) 32,307 (6.4) 0.88 (0.74–1.04) p = 0.14
Migraine 8 (0.3) 3697 (0.7) 0.84 (0.42–1.69) p = 0.64
Hypertension 1087 (41.1) 192,833 (38.0) 0.82 (0.76–0.89)
Bronchiectasis 11 (0.4) 2311 (0.5) 0.81 (0.46–1.48) p = 0.50
Chronic kidney disease 226 (8.6) 31,719 (6.3) 0.80 (0.70–0.91)
aAll differences significant at p < 0.001 except where stated
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known that cardiac dysfunction is present in PD with
cardiac sympathetic denervation being associated with
orthostatic symptoms [29], there have been no previous
reports of an increased prevalence of coronary heart dis-
ease in PD. Although hypertension and chronic kidney
disease were more common in the PD group, after ad-
justment for age, sex and deprivation there was a lower
relative prevalence of these conditions compared with
controls. PD is associated with autonomic impairment
with orthostatic hypotension, which is often associated
with supine hypertension, which would be missed in anormal consultation setting. Supine hypertension is pos-
sibly the explanation for the increase in prevalence of
stroke in PD [30]. Cerebrovascular disease may be a
contributory factor to the progression of dementia and
maintenance of cerebrovascular health, including man-
aging hypertension, may offer an opportunity for redu-
cing the cognitive decline seen in PD [31].
Psychiatric co-morbidity
The psychiatric conditions which had higher prevalence
in the PD group included dementia, depression and anx-
iety and fit with the known neuropsychiatric associations
Table 4 Prevalence and odds ratios for individual mental health conditions (standardised by age, gender and deprivation score).
Conditions are ordered by size of odds ratio (largest too smallest)
Condition Parkinson’s
N (prevalence %)
N = 2640
No Parkinson’s
N (prevalence %)
N = 507,862
Odds ratio (95% CI) (standardised
by age, gender and deprivation)a
Schizophrenia (and related non-organic psychosis) or bipolar disorder 92 (3.5) 5216 (1.0) 3.77 (3.05–4.66)
Dementia 319 (12.2) 10,873 (2.1) 3.31 (2.91–3.77)
Learning Disability 15 (0.6) 1337 (0.3) 3.06 (1.82–5.13)
Depression 738 (28.0) 62,774 (12.4) 3.02 (2.76–3.29)
Anxiety & other neurotic, stress related & somatoform disorders 431 (16.3) 32,991 (6.5) 2.32 (2.08–2.59)
Alcohol misuse 83 (3.1) 18,454 (3.6) 1.01 (0.81–1.27) p = 0.87
Anorexia or bulimia 5 (0.2) 1007 (0.5) 0.91 (0.38–2.21) p = 0.85
aAll differences significant at p < 0.001 except where stated
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common in PD and may be persistent in a proportion of
patients [32] they are also recognised premorbid features
of PD before motor symptoms develop, reflecting early
limbic pathology [33]. Dementia develops in over 80% of
people with PD after 15–20 years [34] and is associated
with the spread of PD pathology to the hippocampus
and cerebral cortex and increasing age [35]. The in-
creased prevalence of schizophrenia and learning disabil-
ity may be explained by the use of psychotropic agents
in these conditions causing Parkinsonism.
Polypharmacy
There was a significantly higher level of polypharmacy
in the PD group compared with controls even after
controlling for the number of conditions. This will at
least partly reflect the complex nature of the treatment
of PD itself, but will also reflect treatments for comor-
bidities. It is not uncommon for patients to receive
combinations of three or more medications for the
motor disorder as well as additional medications for
mood disorders, psychosis and dementia. A systematic
review analysed the reasons behind poor medication
adherence in PD found that drug regimen complexityTable 5 Prevalence and odds ratios for repeat prescribing, standard
Number of active repeat medicationsa Parkinson’s
N (prevalence %)
N = 2640
None 191 (7.2)
One 122 (4.6)
Two 167 (6.3)
Three 230 (8.7)
Four 252 (9.6)
Five to nine 1172 (44.5)
Ten or more 506 (19.2)
aAuthorised for repeat issue without a consultation and issued in the last 84 days
bAll differences significant at p < 0.001 except where statedand polypharmacy were among the factors associated
with poor adherence [36].
Strengths and weaknesses
Strengths of this study include the large sample, which is
representative of the Scottish population derived from
314 primary care practices. Such a large sample of ‘real
world’ patients may have some advantages over a classic
epidemiological study, which would almost certainly be
much smaller and less representative. Using Read Codes
to identify both the index condition (PD) and multiple
medical comorbidities represents a trade-off between
diagnostic accuracy and real-world representativeness.
Estimates for some conditions may have been prone to
bias. Finally, as a cross-sectional study we cannot make
any inferences about casual relationships.
Implications for policy and practice
The co-occurrence of PD with dementia and depression
significantly increases the chance of mortality [37]. The
presence of co-morbidity, particularly psychiatric mor-
bidity emphasises the importance of collaborative multi-
disciplinary care between primary care and secondary
care services including mental health services. One smallised by age, gender and number of physical conditions
No Parkinson’s
N (prevalence %)
N = 507,862
Odds ratio (95% CI)
Directly standardised for age, sex,
and number of physical conditionsb
148,615 (29.3) 0.38 (0.32 to 0.45)
56,729 (11.2) 0.61 (0.51 to 0.73)
53,903 (10.6) 0.71 (0.60 to 0.83)
48,760 (9.6) 0.91 (0.80 to 1.05) p = 0.23
44,000 (8.7) 0.95 (0.83 to 1.08) p = 0.46
124,619 (24.5) 1.40 (1.28 to 1.53)
31,236 (6.2) 1.90 (1.68 to 2.15)
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consultations in primary care over 1 year and found that
the majority of the consultations were for comorbid con-
ditions rather than PD itself, which was largely seen in
secondary care clinics [38]. Comorbidity was associated
with a higher number of consultations and home visits
[39]. The significant polypharmacy seen in PD also offers
a challenge particularly in the presence of co-morbidity,
advancing disease with increased mortality, requiring
prioritisation of medications linked with the patient’s
own priorities.
Conclusions
This study confirms that PD is associated with signifi-
cant physical and mental co-morbidity much of which is
likely to be due to the complex nature of the disease
itself. Polypharmacy is a significant issue in PD due to
the complex nature of the treatments to control motor
function as well as additional treatments used for the
associated mental health disorders. The relative imbal-
ance between the increased prevalence of coronary
disease and lower prevalence of hypertension in this
study requires further study since vascular factors may
have a significant role in the progression of PD to
dementia. The complex nature of co-morbidity and
polypharmacy in PD require services to be well co-
ordinated with the patient’s wishes central to complex
decision making as the condition advances.
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